Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.

Garrel R, Mazel M, Perriard F, Vinches M, Cayrefourcq L, Guigay J, Digue L, Aubry K, Alfonsi M, Delord JP, Lallemant B, Even C, Daurès JP, Landais P, Cupissol D, Alix-Panabières C.

Clin Chem. 2019 Oct;65(10):1267-1275. doi: 10.1373/clinchem.2019.305904. Epub 2019 Aug 6.

PMID:
31387885
2.

[Diagnostic and treatment pitfalls and guidelines for variants of squamous cell carcinomas of the head and neck: on behalf of the REFCOR].

Thariat J, Hourseau M, Baglin AC, Digue L, Vulquin N, Badoual C, Baujat B, Janot F, Ferrand FR, Barry B.

Bull Cancer. 2019 Apr;106(4):395-403. doi: 10.1016/j.bulcan.2019.01.015. Epub 2019 Mar 13. French.

PMID:
30878134
3.

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F.

Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13.

PMID:
30811063
4.

Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report.

Daste A, Digue L, Ravaud A, Domblides C.

Oral Oncol. 2019 Feb;89:150-152. doi: 10.1016/j.oraloncology.2019.01.002. Epub 2019 Jan 11. No abstract available.

PMID:
30639133
5.

Are there variations in adherence to colorectal cancer clinical guidelines depending on treatment place and recommendation novelty? The French EvaCCoR observational study.

Lamy S, Guimbaud R, Digue L, Cirilo-Cassaigne I, Bousser V, Oum-Sack E, Goddard J, Bauvin E, Delpierre C, Grosclaude P; EvaCCoR Group.

Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):346-356. doi: 10.1016/j.clinre.2018.10.008. Epub 2018 Nov 15.

PMID:
30447905
6.

Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy.

Daste A, De-Mones E, Cochin V, Dupin C, Digue L, Ravaud A, Domblides C.

Oral Oncol. 2018 Jun;81:116-118. doi: 10.1016/j.oraloncology.2018.04.013. Epub 2018 Apr 24. No abstract available.

PMID:
29703607
7.

Induction chemotherapy with the EXTREME regimen in frail patients with locally advanced head and neck squamous cell carcinoma.

Cochin V, de Mones E, Digue L, Garcia-Ramirez M, Dupin C, Majoufre C, Fernandez P, Daste A.

Target Oncol. 2018 Apr;13(2):247-252. doi: 10.1007/s11523-018-0552-7.

PMID:
29404898
8.

[Crossed perceptions about malnutrition in patients and their doctors in oncology].

Raynard B, Hébuterne X, Goldwasser F, Ait Hssain A, Dubray Longeras P, Barthélémy P, Rosso E, Phoutthasang V, Bories C, Digue L, Laharie D, Desport JC, Falkowski S, Lacau Saint Guily J, Gyan E.

Bull Cancer. 2017 Nov;104(11):921-928. doi: 10.1016/j.bulcan.2017.09.014. Epub 2017 Nov 8. French.

PMID:
29128080
9.

Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.

Ravaud A, Gomez-Roca C, Picat MQ, Digue L, Chevreau C, Gimbert A, Chauzit E, Sitta R, Cornelis F, Asselineau J, Aziza R, Daste A, Quemener C, Baud J, Bikfalvi A, Pedenon-Périchout D, Doussau A, Molimard M, Delord JP.

Eur J Cancer. 2017 Nov;85:39-48. doi: 10.1016/j.ejca.2017.07.031. Epub 2017 Sep 5.

PMID:
28886476
10.

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.

Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C, Wemeau JL, Gimbert A, Picat MQ, Pedenon D, Digue L, Daste A, Catargi B, Delord JP.

Eur J Cancer. 2017 May;76:110-117. doi: 10.1016/j.ejca.2017.01.029. Epub 2017 Mar 20.

PMID:
28301826
11.

Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.

Daste A, de Mones E, Digue L, François L, Domblides C, Dupin C, Bigourdan A, Ravaud A.

Oral Oncol. 2017 Jan;64:e1-e3. doi: 10.1016/j.oraloncology.2016.10.020. Epub 2016 Nov 3. No abstract available.

PMID:
27818058
12.

m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature.

Daste A, de Mones E, Dupin C, François L, Ravaud A, Digue L.

Oral Oncol. 2016 Nov;62:e1-e2. doi: 10.1016/j.oraloncology.2016.08.008. Epub 2016 Aug 30. Review. No abstract available.

PMID:
27589913
13.

Prise en charge des tumeurs germinales du testicule en Aquitaine : état des lieux des pratiques en 2012.

Ferretti L, Gross-Goupil M, Sargos P, Cirilo Cassaigne I, Gaucher B, Demeaux H, Bousser V, Lebras Y, Pasticier G, Richaud P, Yacoub M, Roubaud G, Digue L.

Prog Urol. 2015 Nov;25(13):855. doi: 10.1016/j.purol.2015.08.280. French. No abstract available.

PMID:
26544475
14.

Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up.

Sagardoy T, Fernandez P, Ghafouri A, Digue L, Haaser T, de Clermont-Galleran H, Castetbon V, de Monès E.

Head Neck. 2016 Apr;38 Suppl 1:E1271-6. doi: 10.1002/hed.24204. Epub 2015 Aug 28.

PMID:
26315809
15.

Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.

Henriques de Figueiredo B, Zacharatou C, Galland-Girodet S, Benech J, De Clermont-Gallerande H, Lamare F, Hatt M, Digue L, De Mones del Pujol E, Fernandez P.

Strahlenther Onkol. 2015 Mar;191(3):217-24. doi: 10.1007/s00066-014-0752-8. Epub 2014 Sep 23.

PMID:
25245468
16.

[Quality assurance in head and neck medical oncology].

Digue L, Pedeboscq S.

Bull Cancer. 2014 May 1;101(5):486-95. doi: 10.1684/bdc.2014.1968. Review. French.

PMID:
24886900
17.

Diagnosis of squamous cell carcinoma metastasis with 18F-FDG PET/CT in stoma after percutaneous endoscopic gastrostomy: a rare and poorly known iatrogenic cause of spread of head and neck cancer.

de Monès E, Castetbon V, Digue L, Baltazart B, Fernandez P.

Clin Nucl Med. 2014 Jun;39(6):544-6. doi: 10.1097/RLU.0b013e3182a23cf6.

PMID:
24810782
18.

[mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].

Ravaud A, Bernhard JC, Gross-Goupil M, Digue L, Ferriere JM.

Bull Cancer. 2010;97:45-51. doi: 10.1684/bdc.2010.1069. Review. French.

PMID:
20418203
19.

Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study.

Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, Bridji B, Digue L, Toubeau M, Grégoire V.

J Clin Oncol. 2010 Mar 1;28(7):1190-5. doi: 10.1200/JCO.2009.24.6298. Epub 2010 Feb 1.

PMID:
20124179
20.

VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.

Ravaud A, Digue L, Trufflandier N, Smith D.

Ann Oncol. 2010 Feb;21(2):431-2. doi: 10.1093/annonc/mdp548. Epub 2009 Nov 26. No abstract available.

PMID:
19945958
21.

Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial.

Salas S, Baumstarck-Barrau K, Alfonsi M, Digue L, Bagarry D, Feham N, Bensadoun RJ, Pignon T, Loundon A, Deville JL, Zanaret M, Favre R, Duffaud F, Auquier P.

Radiother Oncol. 2009 Dec;93(3):503-9. doi: 10.1016/j.radonc.2009.05.016. Epub 2009 Jun 11.

PMID:
19524315
22.

[Hand-foot syndrome and sorafenib].

Milano G, Mortier L, Digue L, Desmedt E, Ravaud A.

Bull Cancer. 2009 Feb;96(2):191-7. doi: 10.1684/bdc.2008.0814. French.

23.

Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: a retrospective 35-year study of 12 patients.

Bégu-Le Corroller A, Valéro R, Moutardier V, Henry JF, Le Treut YP, Gueydan M, De Micco C, Sierra M, Conte-Devolx B, Oliver C, Raccah D, Favre R, Digue L, Heim M, Seitz JF, Delpero JR, Vialettes B.

Diabetes Metab. 2008 Sep;34(4 Pt 1):343-8. doi: 10.1016/j.diabet.2008.01.013. Epub 2008 Jun 16.

PMID:
18556231
24.

Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital.

Karavasilis V, Digue L, Arkenau T, Eaton D, Stapleton S, de Bono J, Judson I, Kaye S.

Eur J Cancer. 2008 May;44(7):978-82. doi: 10.1016/j.ejca.2008.02.040. Epub 2008 Mar 24.

PMID:
18362066
25.

Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.

Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, Tranchand B, Monjanel-Mouterde S, Guillet P, Nicoara A, Baciuchka M, Bagarry-Liegey D, Lacarelle B, Noble A, Durand A, Favre R.

Ther Drug Monit. 2006 Apr;28(2):212-8.

PMID:
16628133
26.

Totally implantable intravascular devices-related complications: effectiveness of insertion by trained team.

Boulamery-Velly A, Mercier C, Duffaud F, Favre R, Digue L, La Scola B.

J Hosp Infect. 2004 Mar;56(3):248-9. No abstract available.

PMID:
15003679
27.

Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy.

Duffaud F, Digue L, Mercier C, Dales JP, Baciuchka-Palmaro M, Volot F, Thomas P, Favre R.

Eur J Cancer. 2003 Sep;39(14):2050-7.

PMID:
12957460
28.

[Interest of studying the in vitro genotoxicity of an antineoplastic drug on healthy human cells: paclitaxel example].

Digue L, Orsière T, Baciuchka-Palmaro M, Duffaud F, Pompili J, Favre R, Botta A.

Bull Cancer. 2002 Oct;89(10):887-92. French.

29.

Acentromeric micronuclei are increased in peripheral blood lymphocytes of untreated cancer patients.

Baciuchka-Palmaro M, Orsière T, Duffaud F, Sari-Minodier I, Pompili J, Bellon L, De Méo M, Digue L, Favre R, Botta A.

Mutat Res. 2002 Sep 26;520(1-2):189-98.

PMID:
12297159
30.

Osteosarcomas of flat bones in adolescents and adults.

Duffaud F, Digue L, Baciuchka-Palmaro M, Volot F, Perles-Daniel C, Garbe L, Favre R.

Cancer. 2000 Jan 15;88(2):324-32.

PMID:
10640964
32.

Micronucleated lymphocyte rates from head-and-neck cancer patients.

Duffaud F, Orsière T, Digue L, Villani P, Volot F, Favre R, Botta A.

Mutat Res. 1999 Feb 19;439(2):259-66.

PMID:
10023078
33.

[Genotoxic and clastogenic effects of doxorubicin].

Villani P, Orsière T, Duffaud F, Digue L, Bouvenot G, Botta A.

Therapie. 1998 Jul-Aug;53(4):391-5. French.

PMID:
9806010
34.

[Doxorubicin and cisplatin genotoxicity: search for a real indication using the micronucleus test].

Duffaud F, Orsière T, Baciuchka-Palmaro M, Digue L, Favre R, Botta A.

Ann Biol Clin (Paris). 1998 Mar-Apr;56(2):183-7. French.

35.

[Importance of micronucleus tests in cultured binuclear T lymphocytes for the detection of genotoxic events in cancer patients].

Duffaud F, Orsière T, Digue L, Favre R, Botta A.

Bull Cancer. 1998 Mar;85(3):267-71. French.

Supplemental Content

Support Center